• E-mail
• Print
• Comment
• Font Size
• Digg
• del.icio.us
• Discuss article

Power3 Makes Extensive Medical Research Available to Industry Partners; Database of Patient Samples is Basis for Identification of Protein Biomarkers

Posted on: Wednesday, 13 September 2006, 12:00 CDT

Power3 Medical Products, Inc. (OTC: PWRM), a leading developer of proteomic testing and biomarker discovery for early detection and monitoring of neurodegenerative disease and breast cancer, said today it is making its medical research database available to industry partners.

The database - more than 2,000 patient samples from the last five years used to identify more than 500 protein biomarkers - represents the platform for Power3's patent-pending proteomic testing and biomarker discovery methods for early detection, monitoring and staging of a broad range of diseases, including breast cancer, Alzheimer's, Parkinson's, ALS (Lou Gehrig's disease), and other neurodegenerative diseases.

"The database offers a broad spectrum of patient samples from our proteomic research," said Silvia Quintero of Power3's scientific team. "Specimens include human cells, serum, plasma, bone marrow, tissue, biopsies, and breast ductal fluid, backed by strong clinical documentation. This 'living' database is the foundation for our identification of more than 500 protein biomarkers, and continues to expand through Power3's strategic partnerships and world-wide collaborations."

Steven B. Rash, CEO of Power3, said the "ultimate goal of this sample collection is to commercially validate our proteomic science. We believe the entire medical and scientific community must address key global clinical needs in diagnostics and drug targeting. At Power3, we are positioning our products to capture clinical and public awareness and a significant portion of the early detection screening market."

Earlier Detection = Earlier Treatment

"Power3 believes on concentrating on the patient with the disease rather than pure scientific outcome," he said. "Our biomarkers show promise for early detection and identification of disease . . . and with earlier detection should come earlier and more effective treatment."

Over recent weeks, Power 3 has announced what Mr. Rash called "significant progress" in its work using biomarkers for the early detection of Alzheimer's and Parkinson's diseases (see "Power3's Biomarkers 'Show Great Promise' for Alzheimer's Diagnostics and Therapeutics," Business Wire, August 30 and "Power3 Identifies Early-Detection Biomarkers for Parkinson's Disease," Business Wire, September 6).

About Power3 Medical Products

Power3 Medical Products, Inc. (PWRM.PK, www.Power3Medical.com), is a leading proteomics company engaged in the commercialization of protein biomarkers, pathways, and mechanisms of diseases, through the development of diagnostic tests and drug targets for cancer and neurodegenerative diseases. Power3's patent-pending technologies are being used to develop screening and diagnostic tests for the early detection and treatment of disease, and its identified protein biomarkers, drug targets, and diagnostic tests are targeted toward markets with critical unmet needs in areas such as breast cancer and neurodegenerative disease. Power3 operates a state-of-the-art proteomics laboratory in The Woodlands (Houston), Texas.

This press release contains forward-looking statements within the meaning of section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. With the exception of historical information contained herein, the matters discussed in this press release involve risk and uncertainties. Actual results could differ materially from those expressed in any forward-looking statement.

Source: Business Wire

More News in this Category